A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

Protocol No
MACROGENICS-CP-MGD006-01
Principal Investigator
Laura Michaelis
Phase
I
Summary
This study involves research about the study drug MGD006. MGD006 is similar to an antibody a substance in the blood that helps remove foreign substances. MGD006 is made to attach to your cancer cells and to T-cells -- a part of your immune system -- that may help your immune system kill the cancer cells.
Description
The purpose of the study is to find the answers to these research questions:
What are the side effects of MGD006?
What is the highest dose of MGD006 that can be given safely?
How long does MGD006 stay in the blood?
How long does it take for MGD006 to leave the body?
Is MGD006 a possible treatment for AML?
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: